ROS1 and non-small cell lung carcinoma: In the BRAVE study, a multicenter retrospective observational study of single biomarker testing in advanced NSCLC patients in Japan, the proportions of patients who underwent individual biomarker testing for EGFR, ALK, and ROS1 were 97.5, 88.1, and 67.3%, respectively.30